Article
U.S. FDA approves Gilead's long-acting HIV drug Sunlenca
Rating:
0.0
Views:
68
Likes:
1
Library:
1
The U.S. Food and Drug Administration (FDA) on Thursday approved Gilead Sciences Inc's Sunlenca therapy for HIV infections, paving the way for a drug that requires less frequent dosing than existing treatments.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value